Found 2 structures.
Displayed structures from 1 to 2
Expand all compounds
Collapse all compounds
Show all as text (SweetDB notation)
Show all graphically (SNFG notation)
1. Compound ID: 18856
b-D-Xylp-(1-2)-+
|
b-D-GlcpA-(1-2)-+ b-D-Xylp-(1-2)-+ |
| | |
-3)-a-D-Manp6Ac-(1-3)-a-D-Manp-(1-3)-a-D-Manp6Ac-(1- |
Show graphically |
Structure type: structural motif or average structure
Compound class: O-polysaccharide, glucuronoxylomannan
Contained glycoepitopes: IEDB_114701,IEDB_115136,IEDB_115576,IEDB_130701,IEDB_140116,IEDB_140630,IEDB_1406409,IEDB_1406410,IEDB_144983,IEDB_145668,IEDB_151534,IEDB_152206,IEDB_164174,IEDB_167188,IEDB_174332,IEDB_423153,IEDB_76933,IEDB_983930,SB_197,SB_44,SB_67,SB_72
The structure is contained in the following publication(s):
- Article ID: 7421
Cherniak R, Sundstrom JB "Polysaccharide antigens of the capsule of Cryptococcus neoformans" -
Infection and Immunity 62(5) (1994) 1507-1512
The major significance of the capsular polysaccharide of C. neoformans is its role in potentiating opportunistic infections by the yeast. It has the ability to exert a broad spectrum of influences on the immune response, from activation of phagocytic cells and complement components of the alternative pathway, to the induction of specific antibody, T-suppressor cells, DTH responses, and cytokines (51). These biological properties along with the serotype specificities are all determined by the physical properties and chemical structures of the polysaccharide antigens that compose the capsule. There is evidence not only for an association of lethal infections with serotype A in patients with advanced AIDS (34, 56), but also for a role for the capsule in directly influencing the infection of CD4 + cells by HIV (57). Together, these phenomena raise intriguing questions about the possible connection between the chemistry of these capsular antigens and cryptococcal infections in AIDS patients. One speculation is that AIDS creates the optimal physiological conditions for the establishment and spread of cryptococcosis. It has been observed that during the progression of AIDS there is a shift towards a T-2 response (14). This could lead to conditions that would inhibit the cellular immune responses that block dissemination of cryptococcal infections. Thus, an important consideration in the application of vaccine or immune modulation therapies in the treatment of cryptococcosis in AIDS victims would be the design of vaccines that could boost the T-1 immune response. It has been shown that the form and dose of an antigenic challenge can influence the induction of a T-1 or T-2 immune response (61). Recently, Murphy has reported that gamma interferon and interleukin 2 are up-regulated in the spleens of mice that produce anticryptococcal T(DH) and T(AMP) cells in response to immunogenic doses of cryptococcal culture filtrate antigen given with Freund's complete adjuvant (49). Perhaps purified cryptococcal antigens (e.g., MP) conjugated to an appropriate carrier or adjuvant could be used in therapeutic strategies to limit cryptococcosis in immunocompromised individuals. Future investigations of virulence and pathogenicity in the context of defined polysaccharide antigens from encapsulated strains of C. neoformans will contribute to a better understanding of the regulation of cryptococcal infection and immunity at the cellular and molecular levels. This information could lead to (i) the development of effective vaccines, designed to induce not only a sufficient but also an appropriate immune response to cryptococcal antigens, and (ii) a better understanding of how these polysaccharide antigens influence T-1 and T-2 T-cell responses, how they potentiate opportunistic cryptococcosis in HIV-infected individuals, and how virulence and serotypes are related to the molecular structures of these antigens.
antigen, capsular polysaccharide, Cryptococcus neoformans, cryptococcosis
NCBI PubMed ID: 8168912Journal NLM ID: 0246127Publisher: American Society for Microbiology
Correspondence: Cherniak R
Institutions: Department of Chemistry, Georgia State University, University Plaza, Atlanta, USA, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, USA
Expand this compound
Collapse this compound
2. Compound ID: 23468
b-D-Xylp-(1-2)-+
|
b-D-GlcpA-(1-2)-+ |
| |
b-D-Xylp-(1-2)-+ | b-D-Xylp-(1-2)-+ |
| | | |
b-D-Xylp-(1-2)-a-D-Manp-(1-3)-a-D-Manp6Ac-(1-3)-a-D-Manp6Ac-(1-3)-a-D-Manp-(1-3)-a-D-Manp6Ac-(1-1)-EtN |
Show graphically |
Structure type: oligomer
Trivial name: glucuronoxylomannan (GXM)
Compound class: CPS
Contained glycoepitopes: IEDB_114701,IEDB_115136,IEDB_115576,IEDB_120354,IEDB_130701,IEDB_140116,IEDB_140630,IEDB_1406410,IEDB_144983,IEDB_145668,IEDB_152206,IEDB_164174,IEDB_167188,IEDB_174332,IEDB_423153,IEDB_76933,IEDB_983930,SB_197,SB_44,SB_67,SB_72
The structure is contained in the following publication(s):
- Article ID: 9622
Hargett AA, Azurmendi HF, Crawford CJ, Wear MP, Oscarsonc S, Casadevall A, Freedberg DI "The structure of a C. neoformans polysaccharide motif recognized by protective antibodies: A combined NMR and MD study" -
Proceedings of the National Academy of Sciences of the USA 121(7) (2024) e2315733121
Cryptococcus neoformans is a fungal pathogen responsible for cryptococcosis and cryptococcal meningitis. The C. neoformans capsular polysaccharide and shed exopolysaccharide functions both as a key virulence factor and to protect the fungal cell from phagocytosis. Currently, a glycoconjugate of these polysaccharides is being explored as a vaccine to protect against C. neoformans infection. In this combined NMR and MD study, experimentally determined NOEs and J-couplings support a structure of the synthetic decasaccharide, GXM10-Ac3, obtained by MD. GXM10-Ac3 was designed as an extension of glucuronoxylomannan (GXM) polysaccharide motif (M2) which is common in the clinically predominant serotype A strains and is recognized by protective forms of GXM-specific monoclonal antibodies. The M2 motif is characterized by a 6-residue α-mannan backbone repeating unit, consisting of a triad of α-(1→3)-mannoses, modified by β-(1→2)-xyloses on the first two mannoses and a β-(1→2)-glucuronic acid on the third mannose. The combined NMR and MD analyses reveal that GXM10-Ac3 adopts an extended structure, with xylose/glucuronic acid branches alternating sides along the α-mannan backbone. O-acetyl esters also alternate sides and are grouped in pairs. MD analysis of a twelve M2-repeating unit polymer supports the notion that the GXM10-Ac3 structure is uniformly represented throughout the polysaccharide. This experimentally consistent GXM model displays high flexibility while maintaining a structural identity, yielding new insights to further explore intermolecular interactions between polysaccharides, interactions with anti-GXM mAbs, and the cryptococcal polysaccharide architecture.
NMR, structure, polysaccharide, Cryptococcus neoformans, Applied Biological Science, Biological Sciences - Biochemistry, Biophysics and Computational Biology, MD, Physical Sciences - Chemistry
NCBI PubMed ID: 37732210Publication DOI: 10.1073/pnas.2315733121Journal NLM ID: 7505876Publisher: National Academy of Sciences
Correspondence: A. Casadevall
Institutions: Laboratory of Bacterial Polysaccharides, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA, W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, Centre for Synthesis and Chemical Biology, University College Dublin, Belfield, Dublin 4, Ireland
Methods: 13C NMR, 1H NMR, NMR-2D, chemical synthesis, MD simulations, transglycosidic torsion calculations
Expand this compound
Collapse this compound
Total list of structure IDs on all result pages of the current query:
Total list of corresponding CSDB IDs (record IDs):
Execution: 1 sec